Published in RINewsToday on September 21, 2026

For generations, menopause was a health issue that many women were expected to deal with on their own, quietly. Last week, the U.S. Senate Special Committee on Aging took the issue into the public discussion, holding the first congressional hearing devoted exclusively to menopause.

The Sept. 16 hearing brought congressional attention to an issue affecting millions of American women navigating perimenopause, menopause and post-menopause. Approximately 2 million more women enter menopause each year.

Menopause affects women differently, but the symptoms can upend daily life. Women may experience hot flashes, vaginal dryness, insomnia, migraine headaches, brain fog, heart palpitations, mood changes, and changes in metabolism. For some, these symptoms become debilitating, disrupting daily and work routines and quality of life.

Senate Aging Committee Chairman Rick Scott (R-FL) and Ranking Member Kirsten Gillibrand (D-NY) convened the hearing, titled “Half the Country, Zero Hearings: Meeting the Moment to End the Menopause Care Gap in America,” to examine what lawmakers call the nation’s “menopause care gap.”

Medical experts, researchers, and women’s health advocates testified about the lack of research, physician training, and access to treatment.

The Senate Aging Committee hearing was a critical step in elevating this issue to determine what’s needed to improve medical research, training, and care for women experiencing menopause,” said Gillibrand in her opening statement.

“Menopause affects half of the population. For generations, women have been told to suffer in silence. I’m done with this silence,” she said.

Even though women in midlife make up a significant portion of the U.S. population, Gillibrand called menopause “one of the most under-researched, undertreated, and under-discussed” health issues in the nation. She pointed to estimates that less than 1% of federal women’s health research funding goes to menopause.

Gillibrand also noted that about 80% of OB-GYN residents report feeling ill-prepared to discuss menopause or its symptoms. The result, she said, is that many women seeking medical care are left without adequate treatment.

Menopause care also carries an economic cost. Gillibrand cited a Mayo Clinic study estimating that menopause costs the U.S. economy $26.6 billion annually, including $1.8 billion in lost work time.

“There’s simply no excuse for the lack of resources and information to help every woman navigate menopause and the challenges that come with it,” said Scott in his opening statement.

Scott cautioned that there is no “one-size-fits-all solution.” Instead, he called for women to have access to reliable information, qualified health care providers, and treatment options that allow them to make informed decisions about their health.

Scott also pointed to hormone replacement therapy as a safe treatment option for many women, while noting that lack of education and access can make it difficult for women to obtain appropriate treatment.

“We also need providers who have the most up-to-date training and who can clearly discuss treatment options with their patients,” said Scott, pointing to the shortage of health care providers as another barrier to care.

Scott and Gillibrand also announced that they sent a bipartisan letter requesting the Government Accountability Office to examine how the federal government both coordinates and funds menopause research and care. The senators say the report could help identify remaining gaps in research, education and treatment.

More Research Needed

Federal funding for research advancing menopause care is inadequate, Dr. Jean Wactawski-Wende, a SUNY Distinguished Professor who has conducted women’s health research for more than four decades, charged.

“In 1985, the National Institutes of Health put forward a study…the report said we’re not doing enough research on women…I’d argue we are now 35 years later, and we have not come all that far,” she told the committee.

“Clinical trials are the gold standard of evidence, and we do not have enough of those trials in women, especially in postmenopausal women,” added Wactawski-Wende.

She identified four areas needing greater attention: increased federal research on women’s health throughout the lifespan; chronic disease in aging women; better education and clinical care after menopause; and greater attention to healthy behaviors throughout life.

Dr. Lynne M. Coslett-Charlton, a board-certified gynecologist who has practiced in Northeastern Pennsylvania for 27 years, pointed to the U.S. Food and Drug Administration’s recent changes to warning labels for menopausal hormone therapy as a major shift in women’s treatment.

Coslett-Charlton also voiced concern that women might get menopause advice from social media influencers instead of from qualified clinicians. This could, in turn, lead them to buy unregulated supplements and products.

She noted that the American College of Obstetricians and Gynecologists has increased its educational efforts to steer patients toward safe, evidence-based, and medically appropriate care. Coslett-Charlton and ACOG also support passage of the Advancing Menopause Care and Midlife Women’s Health Act.

Training Doctors to Treat Menopause

Jennifer Weiss-Wolf, executive director of NYU Law’s Birnbaum Women’s Leadership Center, urged Congress to make telehealth part of the solution. She told lawmakers that virtual care could help connect women, particularly those in areas without specialists, to providers knowledgeable about menopause.

But telehealth has its own barriers, she cautioned, including poor internet connectivity and inadequate insurance coverage. Weiss-Wolf also warned that physician education about menopause must improve.

“For those who started residency after 2002 — statistically that amounts to more than half of all practicing OB-GYNs in the U.S. today — the majority have not had meaningful or even any menopause training,” she said.

Weiss-Wolf called for modern clinical trials that include millennial and Gen X women, with racial, ethnic and geographic diversity. She also urged researchers to use technology better to collect data and track symptoms.

She called on lawmakers to pass three federal bills to increase research and attention to women’s health: the Advancing Menopause Care and Midlife Women’s Health Act; the Service Women and Veterans Menopause Research Act; and the Hormone Health Data and Research Act.

“I Want to Feel Like Myself Again”

“When I ask patients what they hope to get from their care, I often hear, ‘I want to feel like myself again,’” said Dr. Suzanne Silverman Fenske, an obstetrician-gynecologist and integrative medicine practitioner who has practiced in New York City for nearly two decades.

“They want their energy back, relief from anxiety, and a sense of control over a body that suddenly feels unfamiliar,” she said, adding that she

Fenske told the Senate panel that before menopause, a woman’s risk of chronic disease is generally lower than a man’s. After menopause, that risk increases. She pointed to heart disease, hip fractures and urinary sepsis among the serious health problems facing older women.

Fenske also raised an issue that receives far less attention — how physicians are reimbursed for treating menopausal women.

“There is not much incentive for physicians to take care of menopausal women,” she told lawmakers.

Fenske said low insurance reimbursement makes it difficult for independent physicians to spend the necessary time with menopause patients. Large hospital networks may be better able to absorb those costs, she said, while smaller independent practices cannot.

Like the other witnesses, Fenske highlighted the lack of minimum standards for menopause education in medical residency programs.

Fenske offered lawmakers a striking comparison: OB-GYN residents are required to complete at least 200 vaginal deliveries, but there is no comparable minimum requirement for menopause education.  She called on Congress to push Medicare and the Departments of War and Veterans Affairs to make menopause education part of accreditation standards.

Black Box Warning Changes and Challenges

Menopause treatment has received renewed federal attention under Health and Human Services Secretary Robert F. Kennedy Jr., who announced in November 2025 that the FDA would begin removing its strongest “black box” warnings about cardiovascular disease, breast cancer and probable dementia from hormone replacement therapies, including estrogen. The first six revised labels were approved in February 2026, reflecting the administration’s position that overly broad warnings had discouraged women from seeking effective symptom relief. The change does not mean hormone therapy is risk-free: treatment remains an individual decision, with the FDA emphasizing initiation of systemic therapy before age 60 or within 10 years of menopause. The boxed warning about endometrial cancer remains for systemic estrogen-only products. On September 3, the FDA said it was working with manufacturers to increase estrogen patch supplies after rising demand made them harder to find.

Rhode Island No. 1 in U.S. Menopause Workplace Protections

On June 24, 2025, Gov. Dan McKee signed into law legislation (S 0361), introduced by Sen. Lori Urso (D-Dist. 8, Pawtucket), to support women experiencing menopause under the state’s fair employment statute—making Rhode Island the first state to enact such workplace protections explicitly. Rep. Karen Alzate (D-Dist. 60, Pawtucket, Central Falls) introduced a companion bill (H 6161), which passed by concurrence.

Rhode Island law already prohibits workplace discrimination based on pregnancy, childbirth, and related conditions. This includes requiring employers to provide reasonable accommodations and protecting individuals from being denied employment opportunities or promotions—or terminated—because of these conditions. The new law adds menopause to this list of protected health conditions.

“Menopause is a difficult and personal subject that has been stigmatized in this country,” said Sen. Urso in a statement announcing the bill’s passage. “But as something that affects half our population, it’s time we recognize it as a workforce issue—especially as our workforce ages along with our population. The current lack of protections contributes to inadequate retirement savings and lost leadership opportunities for women and poses an economic challenge for employers facing workforce shortages and the loss of experienced employees,” she says.

“Menopause is not something women choose to experience, and its effects on the mind and body can significantly impact daily life and job performance,” said Rep. Alzate. “Women should not have to risk being penalized or discriminated against at work due to a naturally occurring biological transition,” she says.

Rhode Island’s new law is paving the way for workplaces that actually support women experiencing menopause—and it sets a great example for the rest of the country to follow.

A Final Note…

For the millions of women now going through menopause — and the millions more who will follow them — the Sept. 16 hearing put an issue long discussed quietly in doctors’ offices and among women themselves squarely before Congress.

Whether the hearing ultimately results in more federal research, better physician training, and improved access to care will depend on what lawmakers do next. But after generations of silence, menopause finally received its first congressional hearing.

To read Scott and Gillibrand’s correspondence to GAO on the federal government’s role in Menopause research and education, go to Gillibrand Scott GAO Letter on Menopause

To watch the Sept. 16 Senate Aging Committee hearing, go to Half the Country, Zero Hearings: Meeting… | Senate Committee On Aging.

To read about RI’s new Menopause law, go to Rhode Island First in Nation to Add Workplace Protections for Women Experiencing Menopause – Herb Weiss

___